Form 4: Intelligent Bio Solutions CFO Acquires Shares and Exercises Warrants

Spiro Kevin Sakiris, CFO of Intelligent Bio Solutions, reports acquisition of common stock and exercise of warrants.

Summary

• On March 20, 2024, Spiro Kevin Sakiris, the CFO of Intelligent Bio Solutions Inc., reported transactions involving the company's securities.
• Sakiris acquired 9,394 shares of common stock through the exercise of Series F warrants.
• These warrants were exercised using an alternate cashless exercise formula, resulting in a one-for-one exchange for common stock without additional payment.
• Sakiris also directly owns 314 shares of common stock.
• Following these transactions, Sakiris beneficially owns 19,180 shares indirectly through Anest Holdings Pty Ltd.
• The Series F warrants have an exercise price of $6.60 per share (adjusted for a 1-for-12 reverse stock split) and became exercisable on November 17, 2023.

Sentiment

Score: 5

Explanation: Neutral sentiment as it's a standard regulatory filing detailing stock transactions. The CFO exercising warrants could be seen as a mildly positive signal, but it's not definitively bullish.

Positives

• The CFO's exercise of warrants and acquisition of shares could be interpreted as a sign of confidence in the company's future prospects.

Industry Context

Form 4 filings are a routine part of the US financial markets, providing transparency into the transactions of company insiders. This filing indicates the CFO's activity in acquiring company stock.

Stakeholder Impact

• The CFO's stock transactions may influence investor sentiment.

Key Dates

Keywords

Form 4, Beneficial Ownership, Spiro Kevin Sakiris, Intelligent Bio Solutions, INBS, CFO, Warrants, Stock Options, Securities